Insmed CEO William Lewis files Form 4 stock sale
Insmed Chair and CEO William Lewis reported three sales of Insmed common stock on January 6–8, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Insmed Chair and CEO William Lewis reported three sales of Insmed common stock on January 6–8, 2026. He sold 4,096 shares on January 6 at $173.33, 2,357 shares on January 7 at $175.07, and 3,223 shares on January 8 at $174.17, all reported as open market sales.
According to the filing, these shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. After these transactions, Lewis directly held 315,407 shares of Insmed common stock. He also had indirect beneficial ownership of 233,924 shares held by the Katie Procter Dynasty Trust and 50,500 shares held by the William Lewis Family Legacy Trust.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,223 | $174.17 | $561K |
| Sale | Common Stock | 2,357 | $175.07 | $413K |
| Sale | Common Stock | 4,096 | $173.33 | $710K |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did Insmed (INSM) report for William Lewis?
The filing shows that Chair and CEO William Lewis reported three sales of Insmed common stock on January 6, 7, and 8, 2026, all coded as open market sales.
What is William Lewis’s role at Insmed according to this filing?
William Lewis is identified as a Director and as an Officer, serving as Chair and CEO of Insmed.
AI-generated analysis. How Rhea-AI works. Not financial advice.